JPMorgan Chase & Co. lessened its stake in MEDNAX Inc (NYSE:MD) by 42.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 294,049 shares of the company’s stock after selling 219,119 shares during the quarter. JPMorgan Chase & Co. owned about 0.31% of MEDNAX worth $13,721,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the stock. Point72 Hong Kong Ltd acquired a new stake in MEDNAX during the second quarter worth $172,000. NumerixS Investment Technologies Inc increased its stake in MEDNAX by 147.8% during the second quarter. NumerixS Investment Technologies Inc now owns 5,700 shares of the company’s stock worth $247,000 after acquiring an additional 3,400 shares during the last quarter. Iberiabank Corp acquired a new stake in MEDNAX during the third quarter worth $289,000. Strs Ohio acquired a new stake in MEDNAX during the second quarter worth $365,000. Finally, Financial Architects Inc acquired a new stake in MEDNAX during the third quarter worth $372,000. 98.16% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have issued reports on MD shares. Robert W. Baird cut their target price on MEDNAX from $48.00 to $40.00 and set a “neutral” rating for the company in a research note on Friday, November 2nd. Credit Suisse Group cut their target price on MEDNAX from $55.00 to $50.00 and set an “outperform” rating for the company in a research note on Tuesday, November 6th. BMO Capital Markets cut their target price on MEDNAX from $48.00 to $43.00 and set a “market perform” rating for the company in a research note on Friday, November 2nd. Zacks Investment Research cut MEDNAX from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, UBS Group started coverage on MEDNAX in a research note on Friday, November 16th. They set a “sell” rating and a $37.00 target price for the company. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $51.20.
MD opened at $39.37 on Friday. MEDNAX Inc has a 52 week low of $37.26 and a 52 week high of $63.04. The firm has a market cap of $3.54 billion, a PE ratio of 11.33, a PEG ratio of 1.07 and a beta of 0.32. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.67.
MEDNAX (NYSE:MD) last released its quarterly earnings results on Thursday, November 1st. The company reported $0.94 EPS for the quarter, missing the consensus estimate of $0.97 by ($0.03). MEDNAX had a return on equity of 10.45% and a net margin of 9.50%. The firm had revenue of $896.60 million for the quarter, compared to analysts’ expectations of $908.15 million. During the same quarter in the prior year, the business earned $0.87 earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis. Equities research analysts predict that MEDNAX Inc will post 3.51 earnings per share for the current fiscal year.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Featured Article: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.